Jackson and Miles explore how partial NMDA antagonists work like sophisticated volume controls for brain chemistry, offering breakthrough treatments for depression, chronic pain, and addiction without the harsh side effects of complete receptor blockade.

Partial NMDA antagonists are like a sophisticated volume control; instead of turning the neural music completely off, they bring it down to a manageable level to treat conditions like depression and chronic pain without overwhelming the system.
What is a partial NMDA antagonist?


"Instead of endless scrolling, I just hit play on BeFreed. It saves me so much time."
"I never knew where to start with nonfiction—BeFreed’s book lists turned into podcasts gave me a clear path."
"Perfect balance between learning and entertainment. Finished ‘Thinking, Fast and Slow’ on my commute this week."
"Crazy how much I learned while walking the dog. BeFreed = small habits → big gains."
"Reading used to feel like a chore. Now it’s just part of my lifestyle."
"Feels effortless compared to reading. I’ve finished 6 books this month already."
"BeFreed turned my guilty doomscrolling into something that feels productive and inspiring."
"BeFreed turned my commute into learning time. 20-min podcasts are perfect for finishing books I never had time for."
"BeFreed replaced my podcast queue. Imagine Spotify for books — that’s it. 🙌"
"It is great for me to learn something from the book without reading it."
"The themed book list podcasts help me connect ideas across authors—like a guided audio journey."
"Makes me feel smarter every time before going to work"

Jackson: Hey everyone, welcome back to another personalized episode from BeFreed! I'm Jackson, and I'm genuinely excited to dive into today's fascinating topic with my co-host Miles. We're exploring something that's been making waves in both neuroscience and medicine-partial NMDA antagonists.
Miles: Absolutely, Jackson. I'm Miles, and this is going to be a really cool journey through some cutting-edge brain science. You know, when our listeners ask about partial NMDA antagonists, they're really asking about one of the most intriguing developments in how we understand brain chemistry and treat various conditions.
Jackson: Exactly! And what's so compelling here is that we're not just talking about dry academic theory. We're looking at substances that are literally reshaping how we approach depression, pain management, and even addiction treatment. Miles, should we start by breaking down what makes these compounds so unique?